Abstract: One aspect of the disclosure relates to the use of derivatives of dichlorophenyl urea for treating cancers.

Abstract: Provided herein are compositions including methylene bis[4,4?-(2-chlorophenylureidophenoxyisobutyric acid)] (LR-90) or a pharmaceutically acceptable salt or derivative thereof and methods of use thereof for treating and/or preventing chemotherapy-induced neuropathic pain in a subject in need thereof.

Abstract: One aspect of the disclosure relates to the use of derivatives of dichlorophenyl urea for treating cancers.

Abstract: One aspect of the disclosure relates to derivatives of aryl and heterocyclic ureido aryl and heterocyclic carboxamido isobutyric acids, dichlorophenyl urea, curcumin, and 1,3-diazetidine-2,4-dione, and pharmaceutical compositions thereof. The derivatives disclosed herein can modulate development of adipocytes and various cancer cells, including resistant cancer cells and cancer stem cells. Another aspect of the disclosure relates to the use of the derivatives and pharmaceutical compositions disclosed herein in treatment of obesity and various cancers.

Abstract: One aspect of the disclosure relates to the use of derivatives of dichlorophenyl urea for treating cancers.

Abstract: One aspect of the disclosure relates to the use of derivatives of dichlorophenyl urea for treating cancers.

Abstract: One aspect of the disclosure relates to derivatives of aryl and heterocyclic ureido aryl and heterocyclic carboxamido isobutyric acids, dichlorophenyl urea, curcumin, and 1,3-diazetidine-2,4-dione, and pharmaceutical compositions thereof. The derivatives disclosed herein can modulate development of adipocytes and various cancer cells, including resistant cancer cells and cancer stem cells. Another aspect of the disclosure relates to the use of the derivatives and pharmaceutical compositions disclosed herein in treatment of obesity and various cancers.

Abstract: The present invention provides methods for ameliorating, overcoming, or inhibiting insulin resistance in a subject, comprising administering to the subject an effective amount of a compound selected from the group consisting of LR-90 and LR-102, or a pharmaceutically acceptable salt or derivative thereof. Methods of treating type 2 diabetes and diabetic nephropathy, or preventing or slowing their development are also encompassed by the invention.

Abstract: This invention relates to methods for lowering lipid levels in mammals using compounds that inhibit advanced glycation endproducts (AGEs), LR-9, LR-74 and LR-90. These compounds, which inhibit non-enzymatic protein glycation, also inhibit the formation of advanced lipoxidation endproducts (ALES) on target proteins by trapping intermediates in glycoxidation and lopoxidation and inhibiting oxidation reactions important in the formation of AGEs and ALEs.

Abstract: The present invention provides methods for ameliorating, overcoming, or inhibiting insulin resistance in a subject, comprising administering to the subject an effective amount of a compound selected from the group consisting of LR-90 and LR-102, or a pharmaceutically acceptable salt or derivative thereof. Methods of treating type 2 diabetes and diabetic nephropathy, or preventing or slowing their development are also encompassed by the invention.

Abstract: This invention relates to methods for lowering lipid levels in mammals using compounds that inhibit advanced glycation endproducts (AGEs), LR-9, LR-74 and LR-90. These compounds, which inhibit non-enzymatic protein glycation, also inhibit the formation of advanced lipoxidation endproducts (ALES) on target proteins by trapping intermediates in glycoxidation and lopoxidation and inhibiting oxidation reactions important in the formation of AGEs and ALEs.

Abstract: This invention relates to methods for lowering lipid levels in mammals using compounds that inhibit advanced glycation endproducts (AGEs), LR-9, LR-74 and LR-90. These compounds, which inhibit non-enzymatic protein glycation, also inhibit the formation of advanced lipoxidation endproducts (ALEs) on target proteins by trapping intermediates in glycoxidation and lopoxidation and inhibiting oxidation reactions important in the formation of AGEs and ALEs.